Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis

Gastroenterology

Volumn 147, Issue 1, 2014, Pages

  Hézode, Christophe ^a   Fontaine, Helene ^b   Dorival, Celine ^c   Zoulim, Fabien ^d   Larrey, Dominique ^e   Canva, Valerie ^f   De Ledinghen, Victor ^g   Poynard, Thierry ^h   Samuel, Didier ⁱ   Bourliere, Marc ^j   Alric, Laurent ^k   Raabe, Jean Jacques ^l   Zarski, Jean Pierre ^m   Marcellin, Patrick ⁿ   Riachi, Ghassan ^o   Bernard, Pierre Henri ^p   Loustaud Ratti, Veronique ^q   Chazouilleres, Olivier ^r   Abergel, Armand ^s   Guyader, Dominique ^t   Metivier, Sophie ^u   Tran, Albert ^v   Di Martino, Vincent ^w   Causse, Xavier ^x   Dao, Thong ^y   Lucidarme, Damien ^z   Portal, Isabelle ^aa   Cacoub, Patrice ^h   Gournay, Jerome ^ab   Grando Lemaire, Veronique ^ac   Hillon, Patrick ^ad   Attali, Pierre ^ae   Fontanges, Thierry ^af   Rosa, Isabelle ^ag   Petrov Sanchez, Ventzislava ^ah   Barthe, Yoann ^c   Pawlotsky, Jean Michel ^a   Pol, Stanislas ^b   Carrat, Fabrice ^c,r   Bronowicki, Jean Pierre ^ai   more..

^a HENRI MONDOR HOSPITAL   (France)

^b Université Paris René Descartes ^*  (France)

^c INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^d UNIVERSITÉ DE LYON   (France)

^e HÔPITAL SAINT ELOI   (France)

^f Universitaire Claude Huriez   (France)

^g HAUT LÉVÊQUE HOSPITAL   (France)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ HÔPITAL PAUL BROUSSE   (France)

^j HÔPITAL SAINT JOSEPH   (France)

^k UMR 152 IRD Universite Paul Sabatier   (France)

^l Centre Hospitalier Régional   (France)

^m GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁿ BEAUJON HOSPITAL   (France)

^o HÔPITAL CHARLES NICOLLE   (France)

^p HÔPITAL SAINT ANDRÉ   (France)

^q UNIVERSITY OF LIMOGES   (France)

^r HÔPITAL SAINT ANTOINE   (France)

^s UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^t UNIVERSITÉ DE RENNES 1   (France)

^u CHU PURPAN   (France)

^v UNIVERSITY HOSPITAL OF NICE   (France)

^w UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^x CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^y CAEN UNIVERSITY HOSPITAL   (France)

^z UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

^aa HÔPITAL DE LA CONCEPTION   (France)

^ab HÔTEL DIEU   (France)

^ac UNIVERSITÉ PARIS 13   (France)

^ad UNIVERSITÉ DE BOURGOGNE   (France)

^ae BICÊTRE HOSPITAL   (France)

^af Hôpital P Oudot   (France)

^ag CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^ah French National Agency for Research on AIDS and Viral Hepatitis   (France)

^ai UNIVERSITY HOSPITAL OF NANCY   (France)

more..

Author keywords

Chronic Hepatitis C; CUPIC; DAA; Triple Therapy

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; ASTHENIA; CLINICAL DECISION MAKING; CLINICAL TRIAL; DISEASE SEVERITY; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY FAILURE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OBSERVATIONAL STUDY; PERSONAL EXPERIENCE; PNEUMONIA; PRIORITY JOURNAL; RELAPSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY;

CHRONIC HEPATITIS C; CUPIC; DAA; TRIPLE THERAPY;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; COHORT STUDIES; COMORBIDITY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84902953427     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.03.051     Document Type: Article

References (33)

1. F. Poordad, J. McCone Jr., and B.R. Bacon et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
2. B.R. Bacon, S.C. Gordon, and E. Lawitz et al. Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
3. I.M. Jacobson, J.G. McHutchison, and G. Dusheiko et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
4. S. Zeuzem, P. Andreone, and S. Pol et al. Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
5. S. Bruno, M. Zuin, and A. Crosignani et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study Am J Gastroenterol 104 2009 1147 1158
6. J.L. Dienstag, M.G. Ghany, and T.R. Morgan et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C Hepatology 54 2011 396 405
7. G. N'Kontchou, J. Paries, and M.T. Htar et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis Clin Gastroenterol Hepatol 4 2006 1062 1068
8. A. Sangiovanni, G.M. Prati, and P. Fasani et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients Hepatology 43 2006 1303 1310
9. S. Bruno, T. Stroffolini, and M. Colombo et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study Hepatology 45 2007 579 587
10. V. Mallet, H. Gilgenkrantz, and J. Serpaggi et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C Ann Intern Med 149 2008 399 403
11. T.R. Morgan, M.G. Ghany, and H.Y. Kim et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C Hepatology 52 2010 833 844
12. A.J. van der Meer, B.J. Veldt, and J.J. Feld et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593
13. S. Bruno, M.L. Shiffman, and S.K. Roberts et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis Hepatology 51 2010 388 397
14. F. Marrache, Y. Consigny, and M.P. Ripault et al. Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis J Viral Hepatitis 12 2005 421 428
15. J.A. Carrion, E. Martinez-Bauer, and G. Crespo et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study J Hepatol 50 2009 719 728
16. S. Pol, S.K. Roberts, and P. Andreone et al. Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE phase III study Hepatology 54 2011 374A 375A
17. H. Fontaine, K. Petitprez, and F. Roudot-Thoraval et al. Guidelines for the diagnosis of uncomplicated cirrhosis Gastroenterol Clin Biol 31 2007 504 509
18. S. Chevaliez, M. Bouvier-Alias, and R. Brillet et al. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method Hepatology 46 2007 22 31
19. S. Chevaliez, M. Bouvier-Alias, and J.M. Pawlotsky Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification J Clin Microbiol 47 2009 1726 1732
20. P. Cacoub, M. Bourlière, and J. Lubbe et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals J Hepatol 56 2012 455 463
21. C. Hézode, H. Fontaine, and C. Dorival et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890 J Hepatol 59 2013 434 441
22. S. Bruno, J.M. Vierling, and R. Esteban et al. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis J Hepatol 58 2013 479 487
23. J.M. Vierling, M. Davis, and S. Flamm et al. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response J Hepatol 60 2014 748 756
24. F. Poordad, E. Lawitz, and K.R. Reddy et al. Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection-a randomized trial Gastroenterology 145 2013 1035 1044
25. R. Roomer, B.E. Hansen, and H.L.A. Janssen et al. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C Hepatology 52 2010 1225 1231
26. E.V. Gomez, Y.S. Rodriguez, and L.C. Bertot et al. The natural history of compensated HCV-related cirrhosis: a prospective long-term study J Hepatol 58 2013 434 444
27. W. Alazawi, M. Cunningham, and J. Dearden et al. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection Aliment Pharmacol Ther 32 2010 344 355
28. A. Sangiovanni, G.M. Prati, and P. Fasani et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients Hepatology 43 2006 1303 1310
29. S. Bruno, M. Zuin, and A. Crosignani et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study Am J Gastroenterol 104 2009 1147 1158
30. A.M. Di Bisceglie, M.L. Shiffman, and G.T. Everson et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon N Engl J Med 359 2008 2429 2441
31. J.M. Vierling, S. Zeuzem, and F. Poordad et al. Safety and efficacy of boceprevir/peginterferon/ribavirin (BOC/P/R) combination therapy for chronic HCV G1 patients with compensated cirrhosis: a meta-analysis of five phase 3 clinical trials J Hepatol 58 2013 S576
32. M.S. Sulkowski, D.F. Gardiner, and M. Rodriguez-Torres et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med 370 2014 211 221
33. I.M. Jacobson, R.H. Ghalib, and M. Rodriguez-Torres et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study Hepatology 58 2013 1379A 1380A